Effects of Traumatic Stress Induced in the Juvenile Period on the Expression of Gamma-Aminobutyric Acid Receptor Type A Subunits in Adult Rat Brain

Lu, Cui Yan; Liu, De Xiang; Jiang, Hong; Pan, Fang; Ho, Cyrus S.H.; Ho, Roger

doi:10.1155/2017/5715816

Cited by 20 publications

(18 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormalities in amino acid neurotransmitter systems are postulated to play a critical role in the pathoetiology of MDD [ 38 ]. Stress-induced depression and cognitive impairment have been found to be associated with the reduced expression of the gamma-aminobutyric acid (GABA) receptors in the brain [ 39 ].…”

Section: Resultsmentioning

confidence: 99%

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

Rong

Park

Rosenblat

et al. 2018

IJERPH

View full text Add to dashboard Cite

Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to identify the pretreatment predictors of response to ketamine in TRD as part of MDD and BD. Method: Electronic search engines PubMed/MEDLINE, , and Scopus were searched for relevant articles from inception to January 2018. The search term ketamine was cross-referenced with the terms depression, major depressive disorder, bipolar disorder, predictors, and response and/or remission. Results: Multiple baseline pretreatment predictors of response were identified, including clinical (i.e., Body Mass Index (BMI), history of suicide, family history of alcohol use disorder), peripheral biochemistry (i.e., adiponectin levels, vitamin B12 levels), polysomnography (abnormalities in delta sleep ratio), neurochemistry (i.e., glutamine/glutamate ratio), neuroimaging (i.e., anterior cingulate cortex activity), genetic variation (i.e., Val66Met BDNF allele), and cognitive functioning (i.e., processing speed). High BMI and a positive family history of alcohol use disorder were the most replicated predictors. Conclusions: A pheno-biotype of depression more, or less likely, to benefit with ketamine treatment is far from complete. Notwithstanding, metabolic-inflammatory alterations are emerging as possible pretreatment response predictors of depressive symptom improvement, most notably being cognitive impairment. Sophisticated data-driven computational methods that are iterative and agnostic are more likely to provide actionable baseline pretreatment predictive information.

show abstract

Section: Resultsmentioning

confidence: 99%

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

Rong

Park

Rosenblat

et al. 2018

IJERPH

View full text Add to dashboard Cite

show abstract

“…Elevation of glucocorticoid creates a vulnerability to emotional disturbance (Mak, Tang, Chan, Cheak, & Ho, ); and elevation of corticosterone is associated with increased TPH2 expression (Donner, Montoya, Lukkes, & Lowry, ). Increased TPH2 expression was associated with an increase in leptin and interleukin‐6 (IL‐6) (Reichardt et al., ) and a decrease in GABA (Waider et al., ); which play a key role in the pathogenesis of emotional disturbance (Liu, Ho, & Mak, ; Yang, De Xiang Liu, Pan, Ho, & Ho, ; Lu et al., ).…”

Section: Discussionmentioning

confidence: 99%

Poststroke emotional disturbances and a tryptophan hydroxylase 2 gene polymorphism

Choi-Kwon

Jun

et al. 2018

Brain and Behavior

View full text Add to dashboard Cite

ObjectivesEmotional dysfunction is a common finding in stroke patients. Despite reports on serotonergic involvement in the etiology of poststroke emotional dysfunction (PSED), the role of serotonin synthesizing tryptophan hydroxylase 2 (TPH2) genes in the development of PSED remains unclear.MethodsGenotyping of TPH2 rs4641528 and rs10879355 was performed from genomic DNA of 383 stroke patients collected previously and stored at −70°C. Potential associations between TPH2 genes and poststroke depression (PSD), poststroke emotional incontinence (PSEI), and poststroke anger proneness (PSAP) were investigated 3 months poststroke.ResultsAmong the 383 patients, 69 (18%) had PSD, 41 (11%) had PSEI, and 93 (24%) had PSAP. The TPH2 rs4641528 genotype frequencies differed significantly between patients with and without either PSD or PSEI, although no significant differences were found between the patients with and without PSAP. In multiple logistic regression analysis, PSD was related to the National Institutes of Health Stroke Scale (NIHSS) score at admission (95% confidence interval [CI]: 1.047–1.230, p < .01), modified Rankin scale score at 3 months (95% CI: 0.135–0.848, p < .05), and TPH2 rs4641528 C allele (95% CI: 1.039–5.631, p < .05), whereas PSEI was associated only with the NIHSS score at admission (95% CI: 1.053–1.259, p < .01) and the TPH2 rs4641528 C allele (95% CI: 1.029–11.678, p < .05).ConclusionsOur findings suggest that the TPH2 rs4641528 C allele may play a role in the pathogenesis of PSD and PSEI but not PSAP in Korean stroke patients.

show abstract

“…Further research is required to evaluate the effectiveness of new antidepressants with multiple pharmacodynamic mechanisms (such as agomelatine and vortioxetine) for treating PTSD in refugees (Lu 2018a(Lu , 2018b. It has been suggested that gammaaminobutyric acid (GABA) deficit is implicated in the development of PTSD (Lu 2017), and gabapentin might have a role in treating PTSD in refugees.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

The management of post-traumatic stress disorder and associated pain and sleep disturbance in refugees

Lies

Jones

2019

BJPsych advances

View full text Add to dashboard Cite

SUMMARYMore than 68 million people worldwide have been forcibly displaced and one-third of these are refugees. This article offers an overview of the current literature and reviews the epidemiology and evidence-based psychological and pharmacological management of post-traumatic stress disorder (PTSD), sleep disturbance and pain in refugees and asylum seekers. It also considers the relationship between sleep disturbance and PTSD and explores concepts of pain in relation to physical and psychological trauma and distress. During diagnosis, clinicians must be aware of ethnic variation in the somatic expression of distress. Treatments for PTSD, pain and sleep disturbance among refugees and asylum seekers are essentially the same as those used in the general population, but treatment strategies must allow for cultural and contextual factors, including language barriers, loss of freedom and threat of repatriation.LEARNING OBJECTIVESAfter reading this article you will be able to: •recognise the challenges faced by the large number of refugees worldwide•understand the relationship between PTSD, sleep disturbance and pain in refugees•broadly understand the evidence for psychological and pharmacological therapy for treating PTSD, sleep disturbance and pain in refugees.DECLARATION OF INTERESTNone.

show abstract

Effects of Traumatic Stress Induced in the Juvenile Period on the Expression of Gamma-Aminobutyric Acid Receptor Type A Subunits in Adult Rat Brain

Cited by 20 publications

References 58 publications

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

Poststroke emotional disturbances and a tryptophan hydroxylase 2 gene polymorphism

The management of post-traumatic stress disorder and associated pain and sleep disturbance in refugees

Contact Info

Product

Resources

About